Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis

doi:10.4254/wjh.v18.i3.115411

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

(43)

(44)

(0)

(933)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Mar 27, 2026; 18(3): 115411
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.115411

Full Size Figure Download Figure

Figure 2 Forest plot of outcomes. A: Achieving at least one stage of improvement in fibrosis without worsening of metabolic-associated steatohepatitis; B: Metabolic-associated steatohepatitis resolution without worsening fibrosis; C: At least a two-point improvement in the non-alcoholic fatty liver disease activity score with no worsening of fibrosis; D: Normalized liver fat; E: Enhanced liver fibrosis test score; F: Liver stiffness measurement score. CI: Confidence interval.

Citation: Alam U, Rath S, Ansab M, Kashif A, Sethi FA, Siddiqui HT, Afridi ZAK, Burhan M, Ali MA, Moiz A, Bacha Z, Khan A, Ahmed R, Alatise MB, Kamil KA. Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis. World J Hepatol 2026; 18(3): 115411
URL: https://www.wjgnet.com/1948-5182/full/v18/i3/115411.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i3.115411

Alam U, Rath S, Ansab M, Kashif A, Sethi FA, Siddiqui HT, Afridi ZAK, Burhan M, Ali MA, Moiz A, Bacha Z, Khan A, Ahmed R, Alatise MB, Kamil KA. Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis. World J Hepatol 2026; 18(3): 115411 [DOI: 10.4254/wjh.v18.i3.115411]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.